Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with ...

Regeneron Pharmaceuticals just hit a new 52-week low after UBS dropped its price target and slapped on a neutral rating.

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Regeneron Pharmaceuticals REGN +2.20% Get Free Report has outperformed the market over the past 15 years by 9.69% on an ...

Get the latest news on Regeneron Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Regeneron Pharmaceuticals performance ...

Decades ago, research conducted by Nobel laureates Eugene Fama and Kenneth French posited that small-cap stocks should deliver a premium for investors over the long term, due to the higher risk of ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

SINGAPORE] Amid a flurry of delistings from the Singapore Exchange (SGX), one more privatisation offer – especially that for ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing ...